NCT04075370: Exploring Compensation to Maintain Cognitive Function in Adults Newly Diagnosed With Brain Cancer

NCT04075370
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 30 Years to 65 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must be newly diagnosed brain metastases; Patients must be between the ages of 30-65 years of age
Exclusions: 
https://ClinicalTrials.gov/show/NCT04075370

Comments are closed.

Up ↑